Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

AgelessRx, a pioneer in longevity and telehealth solutions, is expanding its suite of GLP-1 offerings to better serve customers seeking sustainable, medically guided solutions. The updated offering ...

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It’s the latest example of limits imposed by insurance that disrupt treatments for patients.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Looking for undervalued stocks? Check out three top undervalued stocks to buy now in May, 2025 to boost your portfolio.

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

Let's consider two corporations that could help you do better than average in the next decade: Eli Lilly (NYSE: LLY) and ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... While the study primarily looked at the impact of the medications, experts agreed there ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.